Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

AB745 Anti-Collagen Type I Antibody

AB745
500 µL  
Purchase on Sigma-Aldrich

Special Offers

Overview

Replacement Information

Key Spec Table

Species ReactivityKey ApplicationsHostFormatAntibody Type
HELISA, IHC, WBRbSemi-PurifiedPolyclonal Antibody
Description
Catalogue NumberAB745
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionAnti-Collagen Type I Antibody
References
Product Information
FormatSemi-Purified
HS Code3002 15 90
PresentationImmunoglobulin fraction, prepared by ammonium sulfate precipitation and chromatography on DEAE-cellulose, of antiSerum cross-absorbed over immobilized human albumin, immunoglobulin and collagen types III, IV and V.

Product is liquid in 0.15M Sodium Chloride, 10mM Sodium Phosphate pH 7.5 with 0.1% Mannitol and 0.1% Dextran as stabilizers. No preservative.
Quality LevelMQ100
Applications
ApplicationThis Anti-Collagen Type I Antibody is validated for use in ELISA, IH, WB for the detection of Collagen Type I.
Key Applications
  • ELISA
  • Immunohistochemistry
  • Western Blotting
Applications Not Recommended
  • Immunohistochemistry (Paraffin)
Application NotesELISA on human collagen type I: 1:4,000.

Indirect microimmunofluorescent visualization of collagen type I on cryostat sections of human tissue or cultured cells: 1:10-1:40.

Western blot 1:200

Not recommended for use in paraffin treated tissues.

Optimal working dilutions must be determined by the end user.
Biological Information
ImmunogenHuman placental collagen type I
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostRabbit
SpecificityRecognizes Human collagen type I. Some cross reactivity with other proteins.
Species Reactivity
  • Human
Antibody TypePolyclonal Antibody
Entrez Gene Number
Entrez Gene SummaryThis gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome Classical type, Caffey Disease and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor. Two transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish]
Gene Symbol
  • COL1A1
  • OI4
Purification MethodAmmonium sulfater precipitation followed by DEAE chromatography, and immunodeletion
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P02452 # Type I collagen is a member of group I collagen (fibrillar forming collagen).
SIZE: 1464 amino acids; 138911 Da
SUBUNIT: Trimers of one alpha 2(I) and two alpha 1(I) chains. Interacts with MRC2 (By similarity).
SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular matrix (By similarity).
TISSUE SPECIFICITY: Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are mineralized with calcium hydroxyapatite.
PTM: Proline residues at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains. & O-linked glycan consists of a Glc-Gal disaccharide bound to the oxygen atom of a post-translationally added hydroxyl group.
DISEASE: SwissProt: P02452 # Defects in COL1A1 are the cause of Caffey disease [MIM:114000]; also known as infantile cortical hyperostosis. Caffey disease is characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age. & Defects in COL1A1 are a cause of Ehlers-Danlos syndrome type I (EDS-I) [MIM:130000]; also known as Ehlers-Danlos syndrome gravis. Ehlers-Danlos syndrome is a genetically and phenotypically heterogeneous connective-tissue disorder characterized by loose- jointedness and fragile, velvety, stretchable, bruisable skin that heals with peculiar 'cigarette-paper' scars. EDS-I is an autosomal dominant trait. & Defects in COL1A1 are a cause of autosomal dominant Ehlers-Danlos syndrome type VII (EDS-VII) [MIM:130060]; which includes also Ehlers-Danlos syndrome type VII-A1. EDS-VII is characterized by arthrochalasis multiplex congenita, skin hyperextensibility and bruisability. & Defects in COL1A1 are a cause of osteogenesis imperfecta type I (OI-I) [MIM:166200]. OI-I is a dominantly inherited serious newborn disease characterized by bone fragility, normal stature, little or no deformity, blue sclerae and hearing loss in 50% of families. Dentinogenesis imperfecta is rare and may distinguish a subset of OI type I (formation of dentine). & Defects in COL1A1 are a cause of osteogenesis imperfecta type II (OI-II) [MIM:166210]; also known as osteogenesis imperfecta congenita. OI-II is lethal in the perinatal period and is charaterized by calvarial mineralization, beaded ribs, compressed femurs, marked long bone deformity and platyspondyly (congenital flattening of the vertebral bodies). & Defects in COL1A1 are a cause of osteogenesis imperfecta type III (OI-III) [MIM:259420]; also called progressively deforming osteogenesis imperfecta with normal sclerae. OI-III is characterized by progressively deforming bones, usually with moderate deformity at birth, sclerae is variable in color, dentinogenesis imperfecta and hearing loss are common. The stature is very short. & Defects in COL1A1 are a cause of osteogenesis imperfecta type IV (OI-IV) [MIM:166220]. OI-IV is charaterized by normal sclerae, moderate to mild deformity and variable short stature. Dentinogenesis imperfecta is common and hearing loss occurs in some patients. & Genetic variations in COL1A1 are associated with susceptibility to involutional osteoporosis [MIM:166710]; also known as senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mineral density, disrutption of bone microarchitecture, and the alteration of the amount and variety of non-collagenous proteins in bone. Osteoporotic bones are more at risk of fracture. & A chromosomal aberration involving COL1A1 is a cause of dermatofibrosarcoma protuberans (DFSP) [MIM:607907]. Translocation t(17;22)(q22;q13) with PDGF. DFSP is an uncommon, locally aggressive, but rarely metastasizing tumor of the deep dermis and subcutaneous tissue. It typically occurs during early or middle adult life and is most frequently located on the trunk and proximal extremities.
SIMILARITY: SwissProt: P02452 ## Belongs to the fibrillar collagen family. & Contains 1 VWFC domain.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsMaintain for 2 years at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Packaging Information
Material Size500 µL
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
AB745 04053252510786

Documentation

Anti-Collagen Type I Antibody MSDS

Title

Safety Data Sheet (SDS) 

Anti-Collagen Type I Antibody Certificates of Analysis

TitleLot Number
RABBIT ANTI-HUMAN COLLAGEN TYPE I POLYCLONAL ANTIBODY - 2383442 2383442
RABBIT ANTI-HUMAN COLLAGEN TYPE I POLYCLONAL ANTIBODY - 2398855 2398855
RABBIT ANTI-HUMAN COLLAGEN TYPE I POLYCLONAL ANTIBODY - 2459004 2459004
RABBIT ANTI-HUMAN COLLAGEN TYPE I - 2511829 2511829
RABBIT ANTI-HUMAN COLLAGEN TYPE I - 2556282 2556282
RABBIT ANTI-HUMAN COLLAGEN TYPE I - 3187453 3187453
RABBIT ANTI-HUMAN COLLAGEN TYPE I - 3260236 3260236
RABBIT ANTI-HUMAN COLLAGEN TYPE I - 3273643 3273643
RABBIT ANTI-HUMAN COLLAGEN TYPE I - 3298048 3298048
RABBIT ANTI-HUMAN COLLAGEN TYPE I - 3336704 3336704

References

Reference overviewApplicationPub Med ID
Hydrostatic pressure independently increases elastin and collagen co-expression in small-diameter engineered arterial constructs.
Crapo PM, Wang Y
Journal of biomedical materials research Part A  96  673-81. doi  2010

Show Abstract
21268239 21268239
In vitro 3D culture of human chondrocytes using Modified {varepsilon}-caprolactone scaffolds with varying hydrophilicity and porosity.
Olmedilla MP, Lebourg M, Ivirico JL, Nebot I, Giralt NG, Ferrer GG, Soria JM, Ribelles JL
Journal of biomaterials applications  2010

Show Abstract
21586602 21586602
Radix Dipsaci does not improve tendon healing in a rat model of patellar tendon donor site injury.
Kai-ming Chan,Sai-chuen Fu,Wun-chun Hui,Lai-shan Chan,Yun-feng Rui,Ling Qin,Leung-kim Hung
Orthopaedic surgery  2  2009

Show Abstract
22009947 22009947
Leptospira interrogans binds to human cell surface receptors including proteoglycans.
Breiner, DD; Fahey, M; Salvador, R; Novakova, J; Coburn, J
Infection and immunity  77  5528-36  2009

Show Abstract Full Text Article
Western Blotting19805539 19805539
Genipin cross-linked fibrin hydrogels for in vitro human articular cartilage tissue-engineered regeneration.
Emma V Dare, May Griffith, Philippe Poitras, James A Kaupp, Stephen D Waldman, David J Carlsson, Geoffrey Dervin, Christine Mayoux, Maxwell T Hincke
Cells, tissues, organs  190  313-25  2009

Show Abstract
19287127 19287127
In vitro enhancement of collagen matrix formation and crosslinking for applications in tissue engineering: a preliminary study.
Ricky R Lareu, Irma Arsianti, Harve Karthik Subramhanya, Peng Yanxian, Michael Raghunath
Tissue engineering  13  385-91  2007

Show Abstract
17518571 17518571
In situ expression of connective tissue growth factor in human crescentic glomerulonephritis.
Katsuyoshi Kanemoto, Joichi Usui, Kosaku Nitta, Shigeru Horita, Atsumi Harada, Akio Koyama, Jan Aten, Michio Nagata
Virchows Archiv : an international journal of pathology  444  257-63  2004

Show Abstract
14758550 14758550
Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis.
Phillips, Roderick J, et al.
J. Clin. Invest., 114: 438-46 (2004)  2004

15286810 15286810
Peripheral nerve extracellular matrix remodeling in Charcot-Marie-Tooth type I disease.
Camilla Palumbo, Roberto Massa, Maria Beatrice Panico, Antonio Di Muzio, Paola Sinibaldi, Giorgio Bernardi, Andrea Modesti
Acta neuropathologica  104  287-96  2002

Show Abstract
12172915 12172915
Fibrocartilages in the extensor tendons of the interphalangeal joints of human toes
Milz, S, et al
Anat Rec, 252:264-70 (1998)  1998

9776080 9776080

Related Products & Applications

Related Products

Product Families

Categories

Life Science Research > Antibodies and Assays > Primary Antibodies